Pricing & Access· August 18, 2026 · 16 min read
DTX401's August 23 PDUFA: Payers Face a Cornstarch-Replacement Gene Therapy
By Ran Chen#Gene Therapy#Rare Disease#Medicaid
Topic
Gene Therapy
Gene therapy approvals, outcomes evidence, site readiness, payer contracts, and one-time treatment access.
Specialty· August 14, 2026 · 20 min read
Spinal Muscular Atrophy Treatment Access Landscape: Spinraza, Itvisma, & Evrysdi
By Ran Chen#Rare Disease#Gene Therapy#Antisense
Pipeline· August 2, 2026 · 26 min read
In Vivo CAR-T by the Numbers 2026: $17.9B in Deals vs 23 Phase 1 Trials
By Ran Chen#CAR-T#Clinical Trials#Oncology
Approvals· July 27, 2026 · 18 min read
Sickle Cell Disease Treatment Access Landscape: Casgevy, Lyfgenia & Oxbryta
Pipeline· July 17, 2026 · 17 min read
Cell & Gene Therapy Trials by the Numbers: The 2026 Registry Landscape
By Ran Chen#Gene Therapy#CAR-T#Clinical Evidence
Pricing & Access· July 13, 2026 · 17 min read
Duchenne Muscular Dystrophy Access Landscape: Elevidys, Oligonucleotides, and Duvyzat
By Ran Chen#Rare Disease#Gene Therapy#HCPCS Coding
Specialty· July 11, 2026 · 16 min read
Hemophilia Access 2026: Prophylaxis and Gene Therapy Post-Roctavian
By Ran Chen#Gene Therapy#Hematology#Payer Coverage
Pricing & Access· June 28, 2026 · 21 min read
Casgevy Access Guide: CMS CGT Model, State Medicaid Criteria, and the ATC Network
By Ran Chen#Medicaid#Prior Authorization#Gene Therapy
Pricing & Access· June 10, 2026 · 9 min read
CAR-T cell therapy access landscape: seven products in 2026
By Ran Chen#CAR-T#Oncology#Prior Authorization
Manufacturing· June 9, 2026 · 6 min read